Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. News

Press releases

13.05.2019

The mechanism of action of Phytoene applied to dermocosmetic now determined and promoted at the NYSCC Suppliers' day

DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene with an anti-aging action which mechanism...
12.04.2019

DEINOVE invited to present at the 29th congress of the European Society of Clinical Microbiology and Infectious Diseases

Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming...
09.04.2019

Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains

The Institut Pasteur will provide a selection of strains for the DEINOVE platform to evaluate their potential antibiotic and antifungal...
28.03.2019

2018 Annual Results: a year of significant progress

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...
21.03.2019

DEINOVE passes the first milestone of the AGIR program and receives €1.5m from Bpifrance

The robotic platform for extracting and screening antibiotic activities from bacterial strains is now operational for the analysis of...
18.02.2019

DEINOVE announces its financial calendar for 2019

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
31.01.2019

Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner

The test design has been improved for a better assessment of DNV3837 effectiveness in treating Clostridium difficile infections, This will...
10.01.2019

A new website to highlight DEINOVE’s disruptive innovation strategy

The new DEINOVE website displays an updated presentation of DEINOVE’s corporate activities and identity It illustrates the disruptive...
22.11.2018

Deinove will market a 2nd proprietary carotenoid-based cosmetic active ingredient in 2019

After launching Phyt-N-Resist® in 2018, Deinove is developing on its own a 2 nd innovative bio-based carotenoid for the cosmetics market...
21.11.2018

DEINOVE confirms its financing options by renewing its equity line

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...
  • « first
  • ‹ previous
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • next ›
  • last »

News

  • Press releases
  • Events
  • Media
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home